Market Intelligence, Clinical Progress, and High-Purity Reagents for Glyco-Immune Checkpoint Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for Siglec-7 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | Siglec-7 ECD-Fc Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 expressed for native glycosylation. |
View SIGLEC7 Products |
| Gene Delivery | Siglec-7 Promise-ORF / Lentivirus Full-length ORF for stable cell line generation and signaling assays. |
View SIGLEC7 Products |
| Benchmark Ab | Anti-Siglec-7 Recombinant Antibody Recombinant positive control derived from clinical benchmark sequences. |
View SIGLEC7 Products |
| Validator | Siglec-7 siRNA Set For target knockdown verification and specificity validation. |
View SIGLEC7 Products |
| Related Target A | Siglec-9 (CD329) Close homolog co-expressed on NK and myeloid cells; critical for cross-reactivity and dual-targeting screening. |
View SIGLEC9 Products |
| Related Target B | CD22 (Siglec-2) B-cell specific Siglec checkpoint; important for lineage-specific glyco-immune profiling. |
View CD22 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Sialic Acid Binding Dependency | HEK293 expressed recombinant Siglec-7 preserves post-translational glycosylation required for native conformation. |
| Subfamily Cross-Reactivity (Siglec-9/5) | Homolog panel proteins strictly verified by mass spectrometry to guarantee accurate sequence identity. |
| Lack of Controls | Clinical benchmark antibodies (biosimilars) included for assay calibration. |
| False Positives | Validated siRNA sets included for target-specific knockdown verification. |
Live Siglec-7 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for Siglec-7 therapeutics is intensifying, with major players shifting focus from traditional mAbs to multi-specific NK-cell engagers and enzymatic glycan-editing therapies (sialidases). As first-generation glyco-immune checkpoint therapies reach the clinic, the next wave of R&0 is targeting the synergistic blockade of both Siglec-7 and Siglec-9 to overcome the highly sialylated immunosuppressive tumor microenvironment.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody | Boehringer Ingelheim, AbbVie | Solid Tumors, Myeloid Malignancies | Ligand blocking assays (Need high-purity ECD-Fc to compete with sialylated ligands) |
| Sialidase Fusion Proteins | Palleon Pharmaceuticals | Ovarian Cancer, Colorectal Cancer | Enzymatic activity validation (Need native-glycosylated target proteins) |
| Bispecific / NK Engagers | ALX Oncology, Innate Pharma | Hematological Malignancies | Dual-affinity validation (Need stable cell lines generated via Lentivirus) |